Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder

Key Points

• To assess the effectiveness of different disease-modifying treatments in reducing relapse rates in double seronegative neuromyelitis optica spectrum disorder.
• Compared relapse rates in patients receiving disease-modifying treatments versus no treatment.
• Evaluated efficacy of anti-CD20 compared to nonspecific immunosuppressants.
• Treatment with a disease-modifying treatment significantly reduces relapse incidence compared to no treatment.
• Anti-CD20 disease-modifying treatments show a lower relapse incidence than nonspecific immunosuppressants.